Novartis, a leading Swiss drugmaker, reported on Tuesday that its oral multiple sclerosis (MS) medication remibrutinib met the main objectives in two late‑stage clinical trials. The studies demonstrated that remibrutinib was superior to a rival drug in lowering the frequency of disease relapses among patients with relapsing‑remitting multiple sclerosis, the most common form of the condition.
Study design and results
Both trials were double‑blind, randomized Phase III investigations that enrolled thousands of participants across multiple countries. Patients received either remibrutinib or the comparator therapy and were followed for a period of up to 24 months. The primary endpoint in each study was the annualized relapse rate (ARR), a standard measure of how often patients experience new disease attacks.
Remibrutinib reduced the ARR by a statistically significant margin compared with the competitor, translating into fewer relapses and a lower burden of disability for patients. Secondary outcomes, including magnetic resonance imaging (MRI) markers of disease activity and patient‑reported quality‑of‑life scores, also favored the Novartis drug, though the company highlighted the primary relapse‑rate data as the key achievement.
Implications for patients and the market
Multiple sclerosis affects an estimated 2.8 million people in the United States and millions more worldwide. Current treatment options include injectable biologics, oral small‑molecule agents, and infusion therapies, each with varying efficacy and side‑effect profiles. An effective oral therapy that can outperform existing drugs offers a convenient and potentially safer alternative for patients who prefer to avoid injections or infusions.
Novartis executives noted that the positive trial data strengthen the company’s long‑term growth strategy, which relies heavily on innovative therapies in high‑need areas such as neurology, oncology, and rare diseases. The three experimental products highlighted by the firm—remibrutinib for MS, pelacarsen for cardiovascular disease, and the gene‑editing therapy del‑desiran—collectively represent more than $10 billion in projected annual sales at peak market penetration.
Next steps
Novartis plans to submit the trial results to regulatory agencies in the United States, Europe, and other key markets later this year, seeking approval for remibrutinib as a new oral treatment for relapsing‑remitting MS. If approved, the drug could become available to patients within the next 12‑18 months, pending standard review timelines.
Healthcare providers and patient advocacy groups have welcomed the news, emphasizing the importance of expanding therapeutic choices for a disease that often imposes a heavy physical, emotional, and financial toll on families.
Industry context
The MS drug landscape has become increasingly competitive, with several companies racing to develop oral agents that can match or exceed the efficacy of established injectable biologics. Novartis’s success with remibrutinib underscores the broader trend of pharmaceutical innovation focused on patient‑friendly delivery methods and targeted mechanisms of action.
Analysts predict that the approval of remibrutinib could reshape market dynamics, prompting competitors to accelerate their own pipeline programs and potentially leading to price competition that benefits patients and insurers alike.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
